Bioxytran, Inc. (OTCMKTS:BIXT) Sees Significant Decrease in Short Interest

Bioxytran, Inc. (OTCMKTS:BIXT) was the recipient of a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 100 shares, a drop of 99.1% from the September 30th total of 11,600 shares. Based on an average daily trading volume, of 89,700 shares, the short-interest ratio is presently 0.0 days.

Bioxytran Stock Performance

BIXT traded down $0.03 during midday trading on Friday, reaching $0.09. 205,633 shares of the company were exchanged, compared to its average volume of 84,780. Bioxytran has a one year low of $0.07 and a one year high of $0.18. The stock has a market capitalization of $15.15 million, a P/E ratio of -2.85 and a beta of -0.89. The stock’s 50-day simple moving average is $0.10 and its 200 day simple moving average is $0.11.

Bioxytran Company Profile

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.